za section vaccine sold brand name mrnabased vaccine developed german biotechnology company biontech development biontech collaborated american company pfizer carry clinical trials logistics authorized use people provide protection caused infection vaccine given intramuscular composed nucleosidemodified mrna modrna encoding mutated form fulllength spike protein encapsulated lipid initial advice indicated vaccination required two doses given days interval later extended days four months clinical trials began april november vaccine entered phase iii clinical trials people interim analysis study data showed potential efficacy preventing symptomatic infection within seven days second dose serious safety side effects mild moderate severity gone within common include mild moderate pain injection site fatigue reports serious side effects allergic reactions rarea longterm complications vaccine first vaccine authorized stringent regulatory authority emergency first cleared regular december united kingdom first country authorize use emergency authorized use level majority august vaccine became first vaccine approved united states food drug administration distribution storage logistical challenge vaccine needs stored extremely low august bivalent version vaccine pfizerbiontech vaccine bivalent authorized use booster dose individuals twelve years age older united september version bivalent vaccine comirnaty originalomicron authorized booster use united september european union authorized tozinameranfamtozinameran booster versions bivalent vaccine used provide protection caused infection virus eliciting immune response vaccine used reduce morbidity mortality vaccine supplied multidose vial white offwhite sterile preservativefree frozen suspension intramuscular must thawed room temperature diluted normal saline initial course consists two world health organization recommends interval three four weeks doses delaying second dose twelve weeks increases immunogenicity even older adults variants authors pitch study think optimal interval delta variant around eight weeks longer intervals leaving receptors vulnerable third fourth fifth dose added testnegativenote casecontrol study published august found two doses pfizer vaccine effectiveness symptomatic disease caused alpha variant effectiveness symptomatic disease caused delta notably effectiveness one dose pfizer vaccine alpha delta similar effectiveness provided one dose august us centers disease control prevention cdc published study reporting effectiveness infection decreased delta variant became predominant us may due unmeasured residual confounding related decline vaccine effectiveness unless indicated otherwise following effectiveness ratings indicative clinical effectiveness two weeks second dose vaccine generally considered effective estimate lower limit confidence effectiveness generally expected slowly decrease november public health england reported possible extremely small reduction effectiveness symptomatic disease delta sublineage longer intervals second preliminary data suggest effectiveness omicron variant starts decline weeks either initial twodose regimen booster variants effectiveness initial doses starts decline six casecontrol study qatar january september found effectiveness infection peaked ci first month second dose followed slow decline accelerated fourth month reaching months similar trajectory observed symptomatic disease specific variants effectiveness severe disease hospitalization death robust peaking second month remaining almost stable sixth month declining october phase trial showed booster dose given approximately months second dose restored protective effect ci efficacy level symptomatic disease delta december pfizer biontech reported preliminary data indicated third dose vaccine would provide similar level neutralizing antibodies omicron variant seen two doses december private health insurer discovery health collaboration south african medical research council reported realworld data cases south africa omicron variant indicate effectiveness variant two doses hospital admission symptomatic disease protection hospital admission maintained ages groups study bivalent booster effectiveness severe outcomes finland september shown reduced risk severe outcomes among elderly contrast among chronicallyill risk similar among received bivalent vaccine among elderly bivalent booster provided highest protection first two months vaccination thereafter signs waning observed effectiveness among individuals aged years aged years based results preliminary study us centers disease control prevention cdc recommends pregnant women get vaccinated statement british medicines healthcare products regulatory agency mhra commission human medicines chm reported two agencies reached conclusion vaccine safe effective children aged may experts commissioned norwegian medicines agency concluded pfizerbiontech vaccine likely cause ten deaths frail elderly patients norwegian nursing homes said people short life expectancies little gain vaccination real risk adverse reactions last days life dying report new south wales government nsw health australia found pfizerbiontech vaccine safe various forms immunodeficiency immunosuppression though note data said groups limited due exclusion many vaccine earlier trials held notes world health organization advises vaccine among three vaccines alongside moderna astrazeneca deems safe give immunocompromised individuals expert consensus generally recommends vaccination report states vaccines able generate immune response individuals though also note response weaker immunocompromised recommends specific patient groups cancer inflammatory bowel disease various liver diseases prioritised vaccination schedules patients said september pfizer announced clinical trial conducted children aged generated robust response phase iii trials vaccine safety concerns adverse side effects vaccine mild moderate severity gone within similar adult vaccines normal signs body building protection clinical trials common side effects affecting one people order frequency pain swelling injection site tiredness headache muscle aches chills joint pain fever fever common second european medicines agency ema regularly reviews data vaccines safety safety report published september ema based million doses administered european according ema benefits comirnaty preventing continue outweigh risks recommended changes regarding use rare side effects may affect one people include temporary one sided facial drooping allergic reactions hives swelling documented hypersensitivity polyethylene glycol peg rare allergy listed contraindication pfizer severe allergic reaction observed approximately eleven cases per million doses vaccine according report us centers disease control prevention allergic reactions happened within minutes vaccination mostly among people documented history allergies allergic uks medicines healthcare products regulatory agency mhra advised december people history significant allergic reaction receive december canadian regulator followed suit noting individuals uk history severe allergic reactions carried adrenaline auto injectors treated june israels ministry health announced probable relationship second dose myocarditis small group december may cases myocarditis per million people vaccinated classified mild spent four days since april increasing number cases myocarditis pericarditis reported united states per million young people mostly male age vaccination moderna affected individuals recover quickly adequate treatment since february german standing committee vaccination recommends aspiration vaccination precautionary biontech technology vaccine based use nucleosidemodified mrna modrna encodes mutated form fulllength spike protein found surface triggering immune response infection virus modrna sequence vaccine nucleotides consists fiveprime cap five prime untranslated region derived sequence human alpha globin signal peptide bases two proline substitutions designated cause spike adopt prefusionstabilized conformation reducing membrane fusion ability increasing expression stimulating neutralizing codonoptimized gene fulllength spike protein bases followed three prime untranslated region bases combined aes selected increased protein expression mrna polya tail comprising adenosine residues linker sequence adenosine residues bases sequence contains uridine residues replaced proline substitutions spike proteins originally developed middle east respiratory syndrome mers vaccine researchers national institute allergy infectious diseases vaccine research center scripps research jason mclellans team university texas austin previously dartmouth addition mrna molecule vaccine contains following inactive ingredients first four lipids lipids modrna together form nanoparticles act carriers get modrna human cells also polyethylene glycol conjugate ie pegylated pfizer biontech manufacturing vaccine facilities united states europe license distribute manufacture vaccine china purchased fosun alongside investment manufacturing vaccine requires threestage process first stage involves molecular cloning dna plasmids code spike protein infusing escherichia coli bacteria markets stage conducted united small pfizer pilot plant chesterfield near st louis four days growth bacteria killed broken open contents cells purified week half recover desired dna product dna bottled frozen shipment safely quickly transporting dna stage important pfizer used company jet helicopter second stage conducted pfizer plant andover united states biontechs plants dna used template build desired mrna takes four mrna created purified frozen plastic bags size large shopping bag hold million doses bags placed trucks take next third stage conducted pfizer plants portage near kalamazoo united states puurs belgium stage involves combining mrna lipid nanoparticles filling vials boxing vials freezing croda international subsidiary avanti polar lipids providing requisite november major bottleneck manufacturing process combining mrna lipid stage takes four days go mrna lipids finished vials lot must spend several weeks deepfreeze storage undergoing verification qualitycontrol may pfizer plant puurs responsible vials destinations outside united therefore doses administered americas outside united states point time required least two transatlantic flights one take dna europe one bring back finished vaccine february biontech announced would increase production manufacture billion doses raised end march billion doses february pfizer revealed entire sequence initially took days average start finish company making progress reducing time half days production process dedicated rigorous testing quality assurance three pfizer also revealed process requires components relies upon suppliers located vaccine manufacturers normally take several years optimize process making particular vaccine speed costeffectiveness attempting largescale due urgency presented pandemic pfizer biontech began production immediately process vaccine originally formulated laboratory started identify ways safely speed scale biontech announced september signed agreement acquire manufacturing facility marburg germany novartis expand vaccine production fully operational facility would produce million doses per year million doses per month site third biontech facility europe produces vaccine pfizer operates least four production sites united states marburg facility previously specialized cancer immunotherapy end march biontech finished retrofitting facility mrna vaccine production retraining staff obtained approval begin besides making mrna marburg facility also performs step combining mrna lipids form lipid nanoparticles ships vaccine bulk facilities fill finish ie filling boxing april ema authorized increase batch size associated process scale pfizers plant puurs increase expected significant impact supply vaccine european end april reported pfizer started export vaccine doses mexico canada kalamazoo plant much closer geographically countries puurs vaccine delivered vials diluted contain ml vaccine comprising ml frozen ml according vial labels vial contains five ml doses however excess vaccine may used one possibly two additional use low dead space syringes obtain additional doses preferable partial doses within vial italian medicines agency officially authorized use excess doses remaining within single danish health authority allows mixing partial doses two january vial contains six united states vials counted five doses accompanied regular syringes six doses accompanied low dead space vaccine stored thirty days two hours use distribution vaccine stored special containers maintain temperatures lowincome countries limited cold chain capacity ultracold transport storage necessary storage temperatures much lower similar moderna vaccine head indonesias bio farma honesti basyir said purchasing vaccine question worlds fourthmost populous country given necessary cold chain capability similarly indias existing cold chain network handle temperatures far requirements vaccines vaccine infectious disease never produced less several years vaccine existed preventing coronavirus infection virus causes detected december biontech began development vaccine january genetic sequences released chinese center disease control prevention triggering urgent international response prepare outbreak hasten development preventive vaccines development began biontech founder uğur şahin read article medical journal lancet convinced coronavirus china would soon become global pandemic called scientists company cancel vacations start development vaccine january biontech started program project lightspeed develop vaccine new virus based already established developing since leading mrna researcher katalin karikó joined company several variants vaccine created laboratories mainz presented experts paul ehrlich institute meanwhile since pfizer working biontech developing mrna vaccine influenza chief executive officers two companies become personally acquainted came phone calls pfizer ceo albert bourla şahin agreed companies would work together development biontechs two agreed begin work immediately formal written legal agreement place govern new biontech transferred knowhow pfizer next letter intent signed three weeks later formal commercial agreement pfizer biontech vaccine signed january according pfizer research development vaccine cost close biontech received million investment fosun march exchange million shares biontech future development marketing rights april biontech signed partnership pfizer received million including equity investment approximately june biontech received million million financing european commission european investment banks deal biontech started early pandemic banks staff reviewed portfolio came biontech one companies capable developing vaccine european investment bank already signed first transaction biontech september german government granted biontech million million vaccine development pfizer ceo albert bourla said decided taking funding us governments operation warp speed development vaccine wanted liberate scientists bureaucracy comes give reports agree going spend money parallel together etc pfizer enter agreement us eventual distribution vaccine phase trials started germany april us may four vaccine candidates entering clinical vaccine candidate chosen promising among three others similar technology developed choosing biontech pfizer conducted phase trials germany united states fosun performed phase trial china phase studies shown better safety profile three biontech pivotal phase trial lead vaccine candidate began july preliminary results phase clinical trials published october indicated potential safety month european medicines agency ema began periodic review study continuousphase trial phase iii november randomized placebocontrolled observerblind dosefinding vaccine candidateselection efficacy study healthy study expanded assess efficacy safety greater numbers participants reaching tens thousands people receiving test vaccinations multiple countries collaboration pfizer phase iii trial assesses safety efficacy tolerability immunogenicity middose level two injections separated days three age groups years years phase iii results indicating efficacy developed vaccine published november approval eu overall vaccine efficacy confirmed ema clarified second dose administered three weeks first days dose cumulative incidence begins diverge vaccinated group placebo group highest concentration neutralizing antibodies reached days dose younger adults days dose older ongoing phase iii trial scheduled run designed assess ability prevent severe infection well duration immune high antibody activity persists least three months second dose estimated antibody halflife days data one study suggested antibodies might remain detectable around pfizer biontech started phase randomized control trial healthy pregnant women years age older study evaluate mcg placebo administered via intramuscular injection two doses days apart phase ii portion study include approximately pregnant women randomized receive placebo weeks gestation phase iii portion study assess safety tolerability immunogenicity placebo among pregnant women enrolled weeks gestation pfizer biontech announced february first participants received first dose study published march american journal obstetrics gynecology came conclusion messenger rna vaccines novel coronavirus pfizerbiontech moderna vaccines safe effective providing immunity infection pregnant breastfeeding mothers furthermore found naturally occurring antibodies created mothers immune system passed children via placenta andor breastmilk thus resulting passive immunity among child effectively giving child protection disease study also found vaccineinduced immunity among studys participants stronger statistically significant way immunity gained recovery natural infection addition study reported occurrence intensity potential side effects undergoing pregnancy lactating similar expected nonpregnant populations remaining generally minor well tolerated mostly including injection site soreness minor headaches muscles aches fatigue short period january pfizer said finished enrolling children aged years study vaccines safety march pfizer biontech announced initial phase iii trial data vaccine effective aged years age trials younger still research letter published jama reported vaccines appeared safe immunosuppressed organ transplant recipients resulting antibody response considerably poorer nonimmunocompromised population one dose paper admitted limitation reviewing data following first dose twodose cycle november bmj published piece journalist paul thacker alleging poor practice ventavia one companies involved phase iii evaluation trials pfizer report enthusiastically embraced antivaccination activists david gorski commented sciencebased medicine thackers article presented facts without necessary context misleading effect playing seriousness noted although jointly developed comirnaty based biontechs proprietary mrna biontech holds marketing authorization united states european union uk expedited licenses us emergency use authorization eua held jointly pfizer many united kingdoms medicines healthcare products regulatory agency mhra gave vaccine rapid temporary regulatory approval address significant public health issues pandemic december permitted medicines act first vaccine approved national use undergoing large scale first mrna vaccine authorized use united kingdom thus became first western country approve vaccine national although decision fasttrack vaccine criticized united kingdom following countries regions expedited processes approve vaccine use costa hong saudi south united arab united world health organization authorized emergency united states emergency use authorization eua mechanism facilitate availability use medical countermeasures including vaccines public health emergencies current pandemic according food drug administration pfizer applied eua november fda approved application three weeks later december us centers disease control prevention cdc advisory committee immunization practices acip approved recommendations vaccination aged sixteen years following eua issuance biontech pfizer continued phase iii clinical trial finalize safety efficacy data leading application licensure approval vaccine united may us fda also authorized vaccine people aged expanded fda recommendation endorsed acip adopted cdc may october eua expanded include children aged years june eua expanded include children aged six months four years february south african health products regulatory authority sahpra south africa issued section emergency use approval may health canada authorized vaccine people aged may singapores health sciences authority authorized vaccine people aged european medicines agency ema followed suit may june uk medicines healthcare products regulatory agency mhra came similar decision approved use vaccine people twelve years age december swiss agency therapeutic products swissmedic granted temporary authorization vaccine regular use two months receiving application saying vaccine fully complied requirements safety efficacy first authorization standard december committee medicinal products human use chmp european medicines agency ema recommended granting conditional marketing authorization vaccine brand name recommendation accepted european commission february brazilian health regulatory agency approved vaccine standard marketing authorization june approval extended aged twelve pfizers negotiation process brazil latin american countries described bullying contract prohibits state brazil publicly discussing existence terms agreement without formers written consent brazil also restricted donating receiving donations july us food drug administration fda granted priority review designation biologics license application bla vaccine goal date decision january august fda approved vaccine use aged sixteen years pfizerbiontech comirnaty vaccine authorized canada september people aged twelve july fda approved vaccine use aged twelve years september chmp ema recommended converting conditional marketing authorizations vaccine standard marketing recommendation covers existing upcoming adapted comirnaty vaccines including adapted comirnaty originalomicron tozinameranriltozinameran comirnaty originalomicron july israels prime minister announced country rolling third dose pfizerbiontech vaccine people age based data suggested significant waning immunity infection time two country expanded availability israelis age five months since second shot august israels coronavirus czar announced israelis received booster shot within six months second dose would lose access countrys green pass vaccine studies performed israel found third dose reduced incidence serious august united states department health human services hhs announced plan offer booster dose eight months second dose citing evidence reduced protection mild moderate disease possibility reduced protection severe disease hospitalization us food drug administration fda centers disease control prevention cdc authorized use additional mrna vaccine dose immunocompromised individuals scientists noted august lack evidence need booster dose healthy people vaccine remains effective severe disease months statement strategic advisory group experts sage said protection infection may diminished protection severe disease likely retained due cellmediated research optimal timing boosters ongoing booster early may lead less robust september fda cdc authorizations extended provide third shot specific october european medicines agency ema stated booster shot vaccine could given healthy people aged years older least six months second also stated people severely weakened immune systems receive extra dose either pfizerbiontech vaccine moderna vaccine starting least days second final approval provide booster shots european union decided national october fda cdc authorized use either homologous heterologous vaccine booster october australian therapeutic goods administration tga provisionally approved booster dose comirnaty people years age january fda expanded emergency use authorization provide use vaccine booster dose aged years age shortened waiting period primary vaccination five months six may fda expanded emergency use authorization provide use vaccine booster dose aged years august fda revoked emergency use authorization monovalent vaccine booster people aged twelve years age older replaced emergency use authorization bivalent vaccine booster dose age october us food drug administration fda centers disease control prevention cdc authorized use either homologous heterologous vaccine booster authorization expanded include adults november august pfizerbiontech vaccine bivalent original omicron short vaccine bivalent received emergency use authorization us food drug administration fda use booster dose individuals aged twelve years age older one dose contains mcg nucleosidemodified messenger rna modrna encoding viral spike glycoprotein strain original mcg modrna encoding glycoprotein omicron variant lineages omicron bivalent vaccine authorized united states different one authorized use united latter contains second modrna component mcg modrna enocoding gylcoprotein earlier september european union authorized booster versions bivalent vaccine people aged twelve years age omicron vaccine tested clinical study omicron vaccine tested preclinical studies according published neutralization responses omicron monovalent omicron mononvalent omicron bivalent original vaccine explored study october fda amended authorization bivalent booster cover people aged five years age december fda amended authorization bivalent booster used third dose people aged six months four years september fda approved updated monovalent single component omicron variant version vaccine comirnaty formula single dose individuals aged twelve years age authorized pfizerbiontech vaccine formula emergency use individuals aged months years approvals emergency authorizations bivalent versions vaccine health canada approved pfizerbiontech comirnaty omicron subvariant monovalent vaccine september uk medicines healthcare products regulatory agency approved used comirnaty omicron vaccine september million doses vaccine including million doses children adolescents years age administered eueea authorization june code name development tozinameran international nonproprietary name comirnaty brand according biontech name comirnaty represents combination terms mrna community famtozinameran inn variant bivalent version raxtozinameran inn xbb variant version pfizer reported revenue million vaccine billion july vaccine development program operation warp speed placed advance order billion pfizer manufacture million doses vaccine use united states vaccine shown safe middecember pfizer agreements supply million doses european million doses million doses million united million doses unspecified number doses million doses fosun also agreements supply million doses hong kong accounts pfizers got way large deal provide billion doses vaccine european union described new york times striking alignment political survival corporate pfizer accused hindering vaccine equity pfizer delivered contractually agreed doses covax programme number equals vaccines produced pfizer company sold doses highincome countries sold none directly lowincome pfizer actively lobbied temporary lift intellectual property rights would allow vaccine produced others without pay royalty videos videosharing platforms circulated around may showing people magnets stick arms receiving vaccine purportedly demonstrating conspiracy theory vaccines contain microchips videos